Calidi Biotherapeutics (CLDI): Rasio rega marang prakiraan pendapatan
Calidi Biotherapeutics (CLDI) success is based on R&D control and passing FDA trials amid stable liquidity. On the GURU.Markets platform, the projected price-to-sales valuation reflects current dynamics, where the parameter value reaches . Development relies on the NeuroNova ecosystem with exclusive clinic supply, while operational activities comply with ESG standards for bio-waste disposal and laboratory energy efficiency.
Rincian analitis perusahaan Calidi Biotherapeutics
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Calidi Biotherapeutics|CLDI - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Calidi Biotherapeutics, Inc.|CLDI - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Calidi Biotherapeutics|CLDI - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Calidi Biotherapeutics|Likuiditas cepet calidibio.com
- rincian asil keuangan lan kelipatan valuasi:
CLDI - Penghasilan resik perusahaan|Bathi mangsa ngarep Calidi Biotherapeutics|CLDI - Rasio rega pasar marang bathi resik|Pangali Forward P/E Calidi Biotherapeutics, Inc.|CLDI - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Calidi Biotherapeutics|CLDI - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Calidi Biotherapeutics|CLDI - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan calidibio.com|CLDI - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Calidi Biotherapeutics
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:Calidi Bio CLDI
Forward P/S measures a company's market value relative to expected revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S metric, an investor can observe capitalization dynamics within the context of risks facing Calidi Biotherapeutics (CLDI), where geopolitical barriers to technology exports could slow drug commercialization and adjust sales forecasts.
Karo sapa Calidi Biotherapeutics saingan
Multiplikator Forward P/S ONC (BeiGene)|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD - Rasio rega marang prakiraan pendapatan|AAPG: Rasio rega marang prakiraan pendapatan|CGON: Multiplikator Forward P/S|URGN - Rasio kapitalisasi marang dodolan sing dikarepake|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PSNL (Personalis Inc)|Multiplikator Forward P/S ERAS|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AURA|Candel - Multiplikator Forward P/S|ARAY: Rasio rega marang prakiraan pendapatan|SLS: Multiplikator Forward P/S|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Citius Oncology, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TuHURA HURA|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|Rasio rega marang pendapatan sing dikarepake FATE|Multiplikator Forward P/S WHWK (Aadi Bioscience)|Rega forward marang dodolan TCRX|Champions Oncology Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep XBiotech Inc.|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|OS Therapies Inc. - Rega forward marang dodolan|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Multiplikator Forward P/S Artiva|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|VERU: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|Xilio Therapeutics Inc (XLO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RENB: Multiplikator forward rega marang pendapatan|MURA - Multiplikator Forward P/S|KAPA (kairospharma.com) - Multiplikator forward rega marang pendapatan|OKUR: Rasio rega marang pendapatan sing dikarepake|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Curis Corp (CRIS) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APLM|Multiplikator forward rega marang pendapatan Tharimmune Corporation THAR|Rasio rega marang prakiraan pendapatan Advanced Biomed ADVB|Rasio kapitalisasi marang dodolan sing dikarepake genprex.com (GNPX)|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|Xenetic Biosciences (XBIO) - Multiplikator forward rega marang pendapatan|Salarius (SLRX) - Rasio rega marang prakiraan pendapatan|PPBT (Kitov Pharma) - Rasio rega marang prakiraan pendapatan|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan BGNE (beigene.com)|Multiplikator Forward P/S CKPT|Rasio kapitalisasi marang dodolan sing dikarepake elevationoncology.com|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|VIRX - Multiplikator Forward P/S|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NAYA|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
